Yasmeen Z. QWAIDER, Sultan S. ABDELHAMID, Loai ALZGHOUL, Mohammad ALDAHABI, Ahmad H. YANIS, Suzan A. ALBDOUR

The association between levels of inflammatory markers in autistic children compared to their unaffected siblings and unrelated healthy controls

Background/aim: Autism spectrum disorder (ASD) describes a range of neurodevelopmental disabilities that impair behavior andcommunication. Although it is relatively prevalent, the pathophysiology is still subject to speculation and debate. The aim of this studyis to identify a possible association between interleukin-6, -8, -9, and -10 and tumor necrosis factor alpha (TNF-α) in autism amongJordanian children by comparing the plasma levels of these cytokines in autistic children with those of their unaffected siblings andunrelated healthy controls.Materials and methods: In this study, 80 Jordanian children under the age of 12 with diagnosed autism were selected. For comparison,51 unaffected siblings and 86 unrelated healthy controls were also recruited. Venous blood was collected and interleukin levels in allthree groups were investigated.Results: Interleukin-6 was found to be significantly higher in the plasma of both autistic children and their siblings compared withthe unrelated healthy control group (P < 0.05). As for interleukin-8 and TNF-α, plasma levels were significantly higher exclusively inautistic children compared to their siblings and unaffected control subjects (P < 0.001, P < 0.001). There was no significant differencebetween plasma levels of the previously mentioned cytokines in the siblings and the unrelated control group. As for interleukin-9 andinterleukin-10, no significant differences were found between all three groups (P = 0.15, P = 0.35).Conclusion: We found that interleukin-8 and TNF-α were exclusively elevated in autistic Jordanian children, while interleukin-6was elevated in both autistic children and their siblings, potentially dismissing its significance. These results may lead to a betterunderstanding of the disorder’s pathophysiology, early testing, and diagnosis.

PDF

___

1. Hervas A. One autism, several autisms. Phenotypical variability in autism spectrum disorders. Revista de Neurología 2016; 62 (1): 9-14.
2. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J et al. Prevalence of autism spectrum disorder among children aged 8 years. Surveillance Summaries 2018; 67 (6): 1-23. doi: 10.15585/mmwr.ss6706a1
3. Chaaya M, Saab D, Maalouf FT, Boustany RM. Prevalence of autism spectrum disorder in nurseries in Lebanon: a cross sectional study. Journal of Autism and Developmental Disorders 2016; 46 (2): 514-522. doi: 10.1007/s10803-015- 2590-7
4. Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W. The impact of neuroimmune alterations in autism spectrum disorder. Frontiers in Psychiatry 2015; 6: 121. doi: 10.3389/ fpsyt.2015.00121
5. Atladóttir HO, Pedersen MG, Thorsen P, Mortensen PB, Delevran B et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009; 124 (2): 687-694. doi: 10.1542/peds.2008-2445
6. Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. American Journal of Psychiatry 2003; 160 (9): 1691-1693. doi: 10.1176/appi.ajp.160.9.1691
7. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain, Behavior, and Immunity 2010; 24 (1): 64-71. doi: 10.1016/J.BBI.2009.08.001
8. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. European Journal of Pharmacology 2004; 500 (1-3): 399-411. doi: 10.1016/J.EJPHAR.2004.07.040
9. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. Journal of Leukocyte Biology 2006; 80 (1): 1-15. doi: 10.1189/jlb.1205707
10. Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology 2017; 42 (1): 284-298. doi: 10.1038/npp.2016.158
11. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators of Inflammation 2015; 2015: 1-10. doi: 10.1155/2015/531518
12. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I et al. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain, Behavior, and Immunity 2011; 25 (1): 40-45. doi: 10.1016/J.BBI.2010.08.003
13. Pan HF, Leng RX, Li XP, Zheng SG, Ye DQ. Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine & Growth Factor Reviews 2013; 24 (6): 515-522. doi: 10.1016/J. CYTOGFR.2013.09.001
14. Tick B, Bolton P, Happe F, Rutter M, Rijsdijk F. Heritability of autism spectrum disorders: a meta-analysis of twin studies. Journal of Child Psychology and Psychiatry 2016; 57 (5): 585- 595. doi: 10.1111/jcpp.12499
15. Saresella M, Marventano I, Guerini FR, Mancuso R, Ceresa L et al. An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children. Biological Psychiatry 2009; 66 (10): 978-984. doi: 10.1016/j. biopsych.2009.06.020
16. Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ et al. Antibrain antibodies in children with autism and their unaffected siblings. Journal of Neuroimmunology 2006; 178 (1-2): 149-155. doi: 10.1016/j.jneuroim.2006.05.025
17. Olmos G, Lladó J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators of Inflammation 2014; 2014: 1-12. doi: 10.1155/2014/861231
18. Zou JY, Crews FT. TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition. Brain Research 2005; 1034 (1-2): 11-24. doi: 10.1016/j.brainres.2004.11.014
19. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Developmental Neuroscience 1994; 16 (3-4): 172-179. doi: 10.1159/000112104
20. Abdallah MW, Larsen N, Grove J, Nørgaard-Pedersen B, Thorsen P et al. Amniotic fluid inflammatory cytokines: potential markers of immunologic dysfunction in autism spectrum disorders. World Journal of Biological Psychiatry 2013; 14 (7): 528-538. doi: 10.3109/15622975.2011.639803
21. Xie J, Huang L, Li X, Li H, Zhou Y et al. Immunological cytokine profiling identifies TNF as a key molecule dysregulated in autistic children. Oncotarget 2017; 8 (47): 82390-82398. doi: 10.18632/oncotarget.19326
22. Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism spectrum disorders, who improved with a luteolincontaining dietary formulation, show reduced serum levels of TNF and IL-6. Translational Psychiatry 2015; 5 (9): 647-647. doi: 10.1038/tp.2015.142
23. Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I et al. Inflammatory activity in autism spectrum disorder. Advances in Experimental Medicine and Biology 2015; 861: 93-98. doi: 10.1007/5584_2015_145
24. El-Ansary A, Al-Ayadhi L. GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. Journal of Neuroinflammation 2014; 11 (1): 189. doi:10.1186/s12974-014-0189-0
25. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Letters 1992; 307(1): 97-101.
26. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I et al. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain, Behavior, and Immunity 2011; 25 (1): 40-45. doi: 10.1016/j.bbi.2010.08.003
27. Li L, Kim J, Boussiotis VA. IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. Journal of Immunology 2010; 185 (7): 4148-4153. doi: 10.4049/jimmunol.1001536
28. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. Journal of Periodontology 1993; 64 (5): 456-460.
29. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology 2005; 57 (1): 67-81. doi: 10.1002/ana.20315
30. Li X, Chauhan A, Sheikh AM, Patil S, Chauhn V et al. Elevated immune response in the brain of autistic patients. Journal of Neuroimmunology 2009; 207 (1-2): 111-116. doi: 10.1016/j. jneuroim.2008.12.002
31. Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T et al. Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder. Journal of Neuroinflammation 2013; 10: 38. doi: 10.1186/1742-2094-10- 38
32. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. Journal of Leukocyte Biology 2006; 80 (2): 227-236. doi: 10.1189/jlb.1105674
33. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The proand anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta - Molecular Cell Research 2011; 1813 (5): 878-888. doi: 10.1016/J.BBAMCR.2011.01.034
34. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharideinduced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. Journal of Immunology 1989; 143 (11): 3517-3523.
35. Petersen AMW, Pedersen BK. The role of il-6 in mediating the anti-inflammatory effects of exercise. Journal of Physiology and Pharmacology 2006; 57: 10:43-51.
36. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. International Journal of Biological Sciences 2012; 8 (9): 1254-1266. doi: 10.7150/ ijbs.4679
37. Molloy CA, Morrow AL, Meinzenn-Derr J, Schleifer K, Dienger K et al. Elevated cytokine levels in children with autism spectrum disorder. Journal of Neuroimmunology 2006; 172 (1-2): 198-205. doi: 10.1016/j.jneuroim.2005.11.007